Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4577529 | 0.87 | KMT2A (0.38) | KDM4EPKMKDM4CKMT2A | |
| SCHEMBL6720560 | 0.87 | KDM4C (0.35) | KDM4EPKMHPGDKDM4CL3MBTL1 | |
| SCHEMBL19991833 | 0.82 | ALDH1A1 (0.39) | KDM4EPKMCNR2KDM4CKMT2A | |
| SCHEMBL19991834 | 0.82 | ALDH1A1 (0.39) | KDM4EPKMCNR2KDM4CKMT2A | |
| SCHEMBL12741097 | 0.79 | CNR2 (0.33) | KDM4EPKMCNR2KMT2AL3MBTL1 | |
| SCHEMBL2876463 | 0.79 | POLB (0.36) | KDM4EPKMKMT2A | |
| SCHEMBL15663509 | 0.79 | KDM4E (0.37) | KDM4EHPGDKDM4CL3MBTL1 | |
| SCHEMBL22832247 | 0.79 | MEN1 (0.38) | KDM4EPKMKDM4CKMT2AL3MBTL1 | |
| SCHEMBL18109605 | 0.79 | MEN1 (0.38) | KDM4EPKMKDM4CKMT2AL3MBTL1 | |
| SCHEMBL18109544 | 0.77 | MEN1 (0.44) | PKMKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| US-7405194-B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | PRAECIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1503749-A4 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARM INC (US) | 2008-04-09 | — | — | EP | disclosed |
| US-7348307-B2 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-03-25 | — | — | US | disclosed |
| WO-2008011114-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| US-7268111-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050130903-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | GLAXOSMITHKLINE LLC | 2005-06-16 | — | — | US | disclosed |
| US-20050059585-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC. (US) | 2005-03-17 | — | — | US | disclosed |
| EP-1503749-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | Praecis Pharmaceuticals Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003092608-A2 | METHIONINE AMINOPEPTIDASE-2 INHIBITORS AND METHODS OF USE THEREOF | PRAECIS PHARMACEUTICALS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| EP-1330447-A2 | PEPTIDES AS MET-AP2 INHIBITORS | Praecis Pharmaceuticals Incorporated (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030109671-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2003-06-12 | — | — | US | disclosed |
| US-6548477-B1 | A carbamate or urea containing comopound is useful to treat angiogeneisis; methionine aminopeptidase 2 (MetAP-2) coupled to a peptide prevents the metabolic degradation of the angiogenesis inhibitor compound | PRAECIS PHARMACEUTICALS INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020193298-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | disclosed |
| US-20020151493-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS INC. | 2002-10-17 | — | — | US | disclosed |
| WO-2002042295-A2 | PEPTIDES AS MET-AP2 INHIBITORS | PRAECIS PHARMACEUTICALS INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | KDM4E 1216/4885PKM 3231/4885CNR2 3537/4885 |
| US-20030109671-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KDM4E 4207/4885PKM 4253/4885CNR2 1140/4885 |
| US-20020193298-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KDM4E 4207/4885PKM 4253/4885CNR2 1140/4885 |
| US-20050130903-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KDM4E 4207/4885PKM 4253/4885CNR2 1140/4885 |
| US-20050059585-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | KDM4E 2242/4885PKM 2690/4885CNR2 2985/4885 |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KDM4E 4207/4885PKM 4253/4885CNR2 1140/4885 |
| US-20020151493-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | KDM4E 4207/4885PKM 4253/4885CNR2 1140/4885 |
| US-20070161570-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, LNPEP | KDM4E 1741/4885PKM 3168/4885CNR2 2009/4885 |
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | KDM4E 1216/4885PKM 3231/4885CNR2 3537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.